Abbott Laboratories (ABL) Stock Forecast & Price Target

Compare

16 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ABL Analyst Ratings

Strong Buy

17 Buy

1 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Abbott

Laboratories

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ABL Stock 12 Month Forecast

Average Price Target

€116.94

▲(23.67% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is €116.94 with a high forecast of €133.15 and a low forecast of €102.81. The average price target represents a 23.67% change from the last price of €94.56.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"92":"€92","113":"€113","134":"€134","102.5":"€102.5","123.5":"€123.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":133.15298636,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€133.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":116.9386606792,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€116.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":102.81433124,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€102.81</span>\n  </div></div>","useHTML":true}}],"tickPositions":[92,102.5,113,123.5,134],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,93.25,96.31946048923076,99.38892097846154,102.4583814676923,105.52784195692308,108.59730244615385,111.66676293538461,114.73622342461539,117.80568391384615,120.87514440307692,123.9446048923077,127.01406538153846,130.08352587076922,{"y":133.15298636,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,93.25,95.07220466763077,96.89440933526154,98.7166140028923,100.53881867052307,102.36102333815384,104.18322800578461,106.00543267341538,107.82763734104616,109.64984200867693,111.47204667630768,113.29425134393846,115.11645601156923,{"y":116.9386606792,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,93.25,93.98571778769231,94.72143557538462,95.45715336307693,96.19287115076924,96.92858893846154,97.66430672615385,98.40002451384615,99.13574230153846,99.87146008923077,100.60717787692307,101.34289566461538,102.07861345230769,{"y":102.81433124,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":120.894,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.999,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.838,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.771,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.199,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.187,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.049,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.662,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.811,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 67,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.253,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.378,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.25,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€133.15

Average Price Target€116.94

Lowest Price Target€102.81

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Josh Jennings

TD Cowen

€115.46

Buy

22.10%

Upside

Reiterated

02/13/26

We think Champion's success will mostly accrue to BSX. However, between ABT's CATALYST trial which recently completed enrollment (see TD Cowen report), and its next-gen Amulet 360 system, we believe ABT can at least retain share in a substantially larger LAAC market opportunity that starts to emerge later this year and become more meaningful in the outyears. We would also highlight that reimbursement coverage gains driven by Champion likely will not be specific to Watchman FLX Pro. This means that BSX and Watchman's coverage gains will provide coattails for the entire LAAC market, benefiting ABT, whose label update from CATALYST could trail BSX's label from Champion by 1 year or more.

Adam Maeder

Piper Sandler

€113.77

Buy

20.32%

Upside

Reiterated

02/06/26

Piper Sandler Sticks to Its Buy Rating for Abbott Laboratories (ABT)

Matt Miksic

Barclays

€119.67

Buy

26.55%

Upside

Reiterated

02/03/26

Analysts Are Bullish on These Healthcare Stocks: Qiagen (QGEN), Abbott Laboratories (ABT)

Brandon Vazquez

William Blair

Buy

―

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Maze Therapeutics, Inc. (NASDAQ: MAZE)

Marie Thibault

BTIG

€117.98

Buy

24.77%

Upside

Reiterated

02/03/26

BTIG Reaffirms Their Buy Rating on Abbott Laboratories (ABT)

Suraj Kalia

Oppenheimer

€117.98→€111.24

Buy

17.64%

Upside

Reiterated

01/23/26

Abbott price target lowered to $132 from $140 at OppenheimerAbbott price target lowered to $132 from $140 at Oppenheimer

Matthew Taylor

Jefferies

€122.2

Buy

29.23%

Upside

Reiterated

01/23/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Maravai Lifesciences Holdings (NASDAQ: MRVI) and CVRx (NASDAQ: CVRX)

Anthony Petrone

Mizuho Securities

€117.98→€105.34

Hold

11.40%

Upside

Reiterated

01/23/26

Abbott price target lowered to $125 from $140 at MizuhoAbbott price target lowered to $125 from $140 at Mizuho

Joanne Wuensch

Citi

€130.62→€117.98

Buy

24.77%

Upside

Reiterated

01/23/26

Abbott price target lowered to $140 from $155 at CitiAbbott price target lowered to $140 from $155 at Citi

Danielle Antalffy

UBS

€133.15

Buy

40.81%

Upside

Reiterated

01/23/26

Analysts Conflicted on These Healthcare Names: Intuitive Surgical (NASDAQ: ISRG) and Abbott Laboratories (NYSE: ABT)

Larry Biegelsen

Wells Fargo

€123.04→€102.81

Buy

8.73%

Upside

Reiterated

01/23/26

Abbott price target lowered to $122 from $146 at Wells FargoAbbott price target lowered to $122 from $146 at Wells Fargo

Lee Hambright

Bernstein

€129.78→€105.34

Buy

11.40%

Upside

Reiterated

01/23/26

Abbott price target lowered to $125 from $154 at BernsteinAbbott price target lowered to $125 from $154 at Bernstein

Vijay Kumar

Evercore ISI

€121.35→€116.3

Buy

22.99%

Upside

Reiterated

01/23/26

Evercore ISI Sticks to Their Buy Rating for Abbott Laboratories (ABT)

Shagun Singh Chadha

RBC Capital

€123.88→€113.77

Buy

20.32%

Upside

Reiterated

01/22/26

Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), BioCryst (BCRX)

Travis Steed

Bank of America Securities

€126.41

Buy

33.68%

Upside

Reiterated

01/19/26

Bank of America Securities Reaffirms Their Buy Rating on Abbott Laboratories (ABT)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Josh Jennings

TD Cowen

€115.46

Buy

22.10%

Upside

Reiterated

02/13/26

Adam Maeder

Piper Sandler

€113.77

Buy

20.32%

Upside

Reiterated

02/06/26

Piper Sandler Sticks to Its Buy Rating for Abbott Laboratories (ABT)

Matt Miksic

Barclays

€119.67

Buy

26.55%

Upside

Reiterated

02/03/26

Analysts Are Bullish on These Healthcare Stocks: Qiagen (QGEN), Abbott Laboratories (ABT)

Brandon Vazquez

William Blair

Buy

―

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Maze Therapeutics, Inc. (NASDAQ: MAZE)

Marie Thibault

BTIG

€117.98

Buy

24.77%

Upside

Reiterated

02/03/26

BTIG Reaffirms Their Buy Rating on Abbott Laboratories (ABT)

Suraj Kalia

Oppenheimer

€117.98→€111.24

Buy

17.64%

Upside

Reiterated

01/23/26

Abbott price target lowered to $132 from $140 at OppenheimerAbbott price target lowered to $132 from $140 at Oppenheimer

Matthew Taylor

Jefferies

€122.2

Buy

29.23%

Upside

Reiterated

01/23/26

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Maravai Lifesciences Holdings (NASDAQ: MRVI) and CVRx (NASDAQ: CVRX)

Anthony Petrone

Mizuho Securities

€117.98→€105.34

Hold

11.40%

Upside

Reiterated

01/23/26

Abbott price target lowered to $125 from $140 at MizuhoAbbott price target lowered to $125 from $140 at Mizuho

Joanne Wuensch

Citi

€130.62→€117.98

Buy

24.77%

Upside

Reiterated

01/23/26

Abbott price target lowered to $140 from $155 at CitiAbbott price target lowered to $140 from $155 at Citi

Danielle Antalffy

UBS

€133.15

Buy

40.81%

Upside

Reiterated

01/23/26

Analysts Conflicted on These Healthcare Names: Intuitive Surgical (NASDAQ: ISRG) and Abbott Laboratories (NYSE: ABT)

Larry Biegelsen

Wells Fargo

€123.04→€102.81

Buy

8.73%

Upside

Reiterated

01/23/26

Abbott price target lowered to $122 from $146 at Wells FargoAbbott price target lowered to $122 from $146 at Wells Fargo

Lee Hambright

Bernstein

€129.78→€105.34

Buy

11.40%

Upside

Reiterated

01/23/26

Abbott price target lowered to $125 from $154 at BernsteinAbbott price target lowered to $125 from $154 at Bernstein

Vijay Kumar

Evercore ISI

€121.35→€116.3

Buy

22.99%

Upside

Reiterated

01/23/26

Evercore ISI Sticks to Their Buy Rating for Abbott Laboratories (ABT)

Shagun Singh Chadha

RBC Capital

€123.88→€113.77

Buy

20.32%

Upside

Reiterated

01/22/26

Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), BioCryst (BCRX)

Travis Steed

Bank of America Securities

€126.41

Buy

33.68%

Upside

Reiterated

01/19/26

Bank of America Securities Reaffirms Their Buy Rating on Abbott Laboratories (ABT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abbott Laboratories

3 Months

xxx

Success Rate

16/20 ratings generated profit

Average Return

+4.15%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +4.15% per trade.

1 Year

Matthew TaylorJefferies

Success Rate

16/20 ratings generated profit

Average Return

+12.68%

reiterated a buy rating 23 days ago

Copying Matthew Taylor's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +12.68% per trade.

2 Years

xxx

Success Rate

15/20 ratings generated profit

Average Return

+31.74%

reiterated a xxx

rating 23 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +31.74% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABL Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ABL has received 40 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. ABL average Analyst price target in the past 3 months is 116.94.

Each month's total comprises the sum of three months' worth of ratings.

ABL Financial Forecast

ABL Earnings Forecast

Next quarter’s earnings estimate for ABL is €0.97 with a range of €0.96 to €1.00. The previous quarter’s EPS was €1.27. ABL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ABL has Performed in-line its overall industry.

ABL Sales Forecast

Next quarter’s sales forecast for ABL is €9.31B with a range of €9.04B to €9.62B. The previous quarter’s sales results were €9.69B. ABL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year ABL has Performed in-line its overall industry.

ABL Stock Forecast FAQ

What is DE:ABL’s average 12-month price target, according to analysts?

Based on analyst ratings, Abbott Laboratories’s 12-month average price target is 116.94.

What is DE:ABL’s upside potential, based on the analysts’ average price target?

Abbott Laboratories has 23.67% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Abbott Laboratories a Buy, Sell or Hold?

Abbott Laboratories has a consensus rating of Strong Buy, which is based on 17 buy ratings, 1 hold ratings and 0 sell ratings.

What is Abbott Laboratories’s share price target?

The average share price target for Abbott Laboratories is 116.94. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €133.15 ,and the lowest forecast is €102.81. The average share price target represents 23.67% Increase from the current price of €94.56.

What do analysts say about Abbott Laboratories?

Abbott Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of Abbott Laboratories?

To buy shares of DE:ABL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Abbott Laboratories (ABL) Stock Forecast & Price Target

ABL Analyst Ratings

ABL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Abbott Laboratories

ABL Analyst Recommendation Trends

ABL Financial Forecast

ABL Earnings Forecast

ABL Sales Forecast

ABL Stock Forecast FAQ

Detailed List of Analyst Forecasts